Hongwu Wang, MD
Internal Medicine · Houston, TXNPI 1396908992
Payments from drug & device makers
Across 24 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$113
- Dexcom, Inc.$54
- Amgen$47
- Biosense Webster, Inc.$38
- Novo Nordisk$36
- Johnson & Johnson$35
- plus $173 from 8 others
What the payments were for
- Food & beverage$495100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 4 | $113 |
| Dexcom, Inc. | 3 | $54 |
| Amgen | 3 | $47 |
| Biosense Webster, Inc. | 1 | $38 |
| Novo Nordisk | 2 | $36 |
| Johnson & Johnson | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| AstraZeneca | 2 | $29 |
| Dynavax Technologies Corporation | 1 | $28 |
| GSK | 1 | $19 |
| Novartis | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Bayer | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$495 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $138,684 |
| JardianceEmpagliflozin | 23 | $33,110 |
| FarxigaDapagliflozin Propanediol | 20 | $31,121 |
| MounjaroTirzepatide | 20 | $24,299 |
| ProliaDenosumab | 14 | $24,114 |
| TrulicityDulaglutide | 12 | $23,300 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,842 |
| Atorvastatin Calcium | 623 | $7,340 |
| Rosuvastatin Calcium | 250 | $5,881 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,238 |
| Levothyroxine Sodium | 385 | $4,106 |
| Amlodipine Besylate | 507 | $3,110 |
| Losartan Potassium | 263 | $2,729 |
| SynthroidLevothyroxine Sodium | 39 | $2,488 |
| Nifedipine ErNifedipine | 77 | $2,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $36 | $138,684106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $15 | $47,59932 claims |
| AstraZenecaFarxiga | $29 | $31,12120 claims |
| AmgenProlia | $47 | $24,11414 claims |
| GSKTrelegy Ellipta | $19 | $13,84212 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $30 | $1,13841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.